CXCL9 and Alzheimer disease: In the CXC motif, the plasma/serum level of CXCL10 (IP-10) was significantly elevated in patients with AD compared with HC, with a large effect size (average ratio, 1.92; 95% CI, 1.03–3.58, p = 0.039; I2 = 99.4%) in 78 AD and 64 controls, and of CXCL9 did so (RoM, 1.78, 95% CI, 1.39–2.28, p < 0001; I2 = 46.9%) in 140 AD and 108 controls.